Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (177 Lu-J591) for Metastatic Castration-Resistant Prostate Cancer.
Muhammad Junaid NiazJaspreet S BatraRyan D WalshMarigdalia K Ramirez-FortShankar VallabhajosulaYuliya S JhanwarAna M MolinaDavid M NanusJoseph R OsborneNeil H BanderScott T TagawaPublished in: The oncologist (2020)
Hyperfractionation of 177 Lu-J591 is feasible but does not seem to have significant advantages over the two-dose fractionation regimen.